FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
about
Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.Retrocrural Lymph Node Metastasis Disclosed by (18)F-FDG PET/CT: A Predictor of Supra-diaphragmatic Spread in Ovarian Cancer.A Case of Meigs' Syndrome: The (18)F-FDG PET/CT Findings.Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benignPrognostic value of metabolic tumor burden in lung cancer.Is 18F-fluorodeoxyglucose positron emission tomography/computed tomography helpful in the decision-making process for neck dissection in patients with T1-T2 lingual cancer?Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.PET Molecular Imaging-Directed Biopsy: A Review.Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinalDetection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management.CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer.SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?Who should undergo a colonoscopy among patients with incidental colon uptake on PET-CT?FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
P2860
Q31113917-7C7F588F-A02D-4832-B772-2DE3D5C3F16FQ33704291-4AB54B6D-C5CD-4B60-8021-71302AED035CQ33704405-0276792F-C9DC-4B63-9B98-5230255E99F4Q34131787-64CCC103-0CF5-457E-808E-B5B75E3D5C25Q35288214-F02A1216-1608-4942-AE1E-A03AD1798005Q37413672-9D859FD4-6F8F-43EE-9626-BAC7DC22DF0BQ38300065-6F0AB935-A05E-42D0-85F9-08BFA0A6BA9FQ38925887-CCAF8AB7-2DBA-48BC-BBB3-5776D37C2AB5Q39306671-61FEBA53-F7CA-4EB4-AF49-53DB88D9020BQ40396280-144A3F57-6C4D-4E31-A964-2277B6E9F345Q44644593-18E50BD8-0D79-4BB1-943C-D0F2747122A2Q47112640-1F5E1AE2-AEF3-43E8-A743-A22A7B73E117Q50878255-C14CDB2D-6FB1-4987-B8D3-E7F9C3EC562DQ53014495-F6D01294-6CEA-44BD-86F4-7A0F8B63223EQ53022103-52D5C4C1-1B13-4613-8B86-0FBCF75B2F52Q53631599-748E817C-8AEF-408D-BF99-C5B8A8FF0067
P2860
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@en
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@nl
type
label
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@en
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@nl
prefLabel
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@en
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
@nl
P2093
P1476
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy
@en
P2093
P2888
P304
P356
10.1007/S00259-001-0736-7
P50
P577
2002-02-27T00:00:00Z